Switch theme
Sign up to access all valuation multiples
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology, where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
2012
12
LTM Revenue $5.1M
LTM EBITDA -$25.5M
$41.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gensight Biologics has a last 12-month revenue (LTM) of $5.1M and a last 12-month EBITDA of -$25.5M.
In the most recent fiscal year, Gensight Biologics achieved revenue of $1.7M and an EBITDA of -$12.8M.
Gensight Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gensight Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.1M | XXX | $1.7M | XXX | XXX | XXX |
| Gross Profit | $5.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$25.5M | XXX | -$12.8M | XXX | XXX | XXX |
| EBITDA Margin | -500% | XXX | -758% | XXX | XXX | XXX |
| EBIT | -$28.0M | XXX | -$17.8M | XXX | XXX | XXX |
| EBIT Margin | -549% | XXX | -1054% | XXX | XXX | XXX |
| Net Profit | -$26.1M | XXX | -$15.7M | XXX | XXX | XXX |
| Net Margin | -513% | XXX | -933% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $12.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gensight Biologics's stock price is EUR 0 (or $0).
Gensight Biologics has current market cap of EUR 25.0M (or $28.1M), and EV of EUR 36.9M (or $41.5M).
See Gensight Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41.5M | $28.1M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gensight Biologics has market cap of $28.1M and EV of $41.5M.
Gensight Biologics's trades at 24.6x EV/Revenue multiple, and -3.2x EV/EBITDA.
Equity research analysts estimate Gensight Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gensight Biologics has a P/E ratio of -1.1x.
See valuation multiples for Gensight Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.1M | XXX | $28.1M | XXX | XXX | XXX |
| EV (current) | $41.5M | XXX | $41.5M | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 24.6x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | -3.2x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -2.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -1.4x | XXX | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGensight Biologics's last 12 month revenue growth is 55%
Gensight Biologics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.6M for the same period.
Gensight Biologics's rule of 40 is -1594% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gensight Biologics's rule of X is -363% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gensight Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 55% | XXX | 111% | XXX | XXX | XXX |
| EBITDA Margin | -500% | XXX | -758% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1594% | XXX | -703% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -363% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 825% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1154% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gensight Biologics acquired XXX companies to date.
Last acquisition by Gensight Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Gensight Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gensight Biologics founded? | Gensight Biologics was founded in 2012. |
| Where is Gensight Biologics headquartered? | Gensight Biologics is headquartered in France. |
| How many employees does Gensight Biologics have? | As of today, Gensight Biologics has 12 employees. |
| Who is the CEO of Gensight Biologics? | Gensight Biologics's CEO is Ms. Laurence Rodriguez. |
| Is Gensight Biologics publicy listed? | Yes, Gensight Biologics is a public company listed on PAR. |
| What is the stock symbol of Gensight Biologics? | Gensight Biologics trades under SIGHT ticker. |
| When did Gensight Biologics go public? | Gensight Biologics went public in 2016. |
| Who are competitors of Gensight Biologics? | Similar companies to Gensight Biologics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Gensight Biologics? | Gensight Biologics's current market cap is $28.1M |
| What is the current revenue of Gensight Biologics? | Gensight Biologics's last 12 months revenue is $5.1M. |
| What is the current revenue growth of Gensight Biologics? | Gensight Biologics revenue growth (NTM/LTM) is 55%. |
| What is the current EV/Revenue multiple of Gensight Biologics? | Current revenue multiple of Gensight Biologics is 8.1x. |
| Is Gensight Biologics profitable? | Yes, Gensight Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gensight Biologics? | Gensight Biologics's last 12 months EBITDA is -$25.5M. |
| What is Gensight Biologics's EBITDA margin? | Gensight Biologics's last 12 months EBITDA margin is -500%. |
| What is the current EV/EBITDA multiple of Gensight Biologics? | Current EBITDA multiple of Gensight Biologics is -1.6x. |
| What is the current FCF of Gensight Biologics? | Gensight Biologics's last 12 months FCF is -$30.7M. |
| What is Gensight Biologics's FCF margin? | Gensight Biologics's last 12 months FCF margin is -602%. |
| What is the current EV/FCF multiple of Gensight Biologics? | Current FCF multiple of Gensight Biologics is -1.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
